Oral Obesity Therapies Market Global Report 2026

The oral obesity therapies market size has grown rapidly in recent years. It will grow from $3.96 billion in 2025 to $4.36 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to the increasing global prevalence of obesity, rising awareness of metabolic health risks, expanding use of prescription-based weight management drugs, growing clinical research into appetite regulation mechanisms, and increasing healthcare emphasis on non-invasive obesity treatments.

The oral obesity therapies market size is expected to see strong growth in the next few years. It will grow to $6.36 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to rising adoption of oral glucagon-like peptide-1 therapies, increasing demand for personalized metabolic treatments, expansion of telemedicine-based obesity care, growing availability of next-generation oral incretin drugs, and rising investments by pharmaceutical companies in obesity drug pipelines. Major trends in the forecast period include increasing adoption of oral glucagon-like peptide-1-based therapies for appetite regulation and weight management, growing use of combination oral obesity drugs targeting multiple metabolic pathways, rising demand for personalized obesity treatments based on genetic and metabolic profiling, expansion of telehealth-enabled prescription access for oral weight loss therapies, and increasing development of oral drugs that modulate gut hormones for improved metabolic control.

The rising demand for emissions reduction in shipping and aviation is expected to propel the growth of the onboard carbon capture system market going forward. Emissions reduction demand refers to the increasing global emphasis on reducing greenhouse gas emissions from sectors that make significant contributions to climate change, including transportation sectors such as shipping and aviation. The demand for emissions reduction in shipping and aviation is increasing as international regulations and climate targets increasingly require operators to reduce greenhouse gas emissions, while customers and investors are also demanding demonstrably cleaner transportation solutions. The onboard carbon capture system market supports emissions reduction in shipping and aviation by providing technologies that capture carbon dioxide at the point of emission from vessels and aircraft, enabling operators to meet increasingly stringent emissions targets. For instance, in July 2023, according to the International Maritime Organization (IMO), a UK-based United Nations specialized agency, the 2023 IMO Strategy on Reduction of GHG Emissions from ships established targets to reduce carbon intensity by at least 40% by 2030, compared with 35% in 2022, and achieve net-zero greenhouse gas emissions by around 2050, demonstrating a clear year-over-year increase in ambition for decarbonization in the shipping sector. Therefore, the rising demand for emissions reduction in shipping and aviation is driving the growth of the onboard carbon capture system market.

Key companies operating in the oral obesity therapies market are focusing on developing innovative solutions such as incretin-based therapy to enhance weight loss efficacy, improve metabolic outcomes, and offer convenient non-injectable treatment options for patients. Incretin-based therapy refers to a class of treatments that mimic or enhance the action of incretin hormones, such as GLP-1, to regulate blood sugar levels, suppress appetite, and promote weight loss. For example, in January 2026, Denmark A/S, a Denmark-based healthcare company, launched an LP-1 pill for obesity, called the Wegovy pill (oral semaglutide), for chronic weight management in adults with obesity or overweight plus related conditions, alongside diet and exercise. It is also cleared to reduce cardiovascular risks such as heart attacks and strokes in those with established heart disease.

In December 2023, Hoffmann-La Roche AG, a Switzerland-based healthcare company, acquired Carmot Therapeutics Inc. for $2.7 billion. Through this acquisition, Roche aims to strengthen its position in the obesity and metabolic disease market by broadening its portfolio of incretin-based therapies, including oral GLP-1 drug candidates, while enhancing its drug discovery and development capabilities. Carmot Therapeutics Inc. is a US-based biotechnology company specializing in oral therapies for obesity.

Major companies operating in the oral obesity therapies market are F. Hoffmann-La Roche AG, Merck & Co. Inc., Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Sun Pharmaceutical Industries Ltd., Jiangsu Hengrui Medicine Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Hanmi Pharmaceutical Co. Ltd., Innovent Biologics Inc., Viking Therapeutics Inc., Rhythm Pharmaceuticals Inc., Septerna Therapeutics, Eccogene Inc., Currax Pharmaceuticals LLC, Ascletis Pharma Inc., Structure Therapeutics.

North America was the largest region in the oral obesity therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral obesity therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oral obesity therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 1-3 business days.